ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting

DUBLIN–(BUSINESS WIRE)–ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organisation, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 25, 2023 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 12, 2023 and are available on the ICON plc website.


Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions:

RESOLUTION NUMBER

RESOLUTION

TOTAL NUMBER OF VOTES

VOTE FOR

VOTE AGAINST

VOTE WITHHELD

1.1

To re-elect Mr. Ciaran Murray

71,566,816

70,257,312

1,283,072

26,432

1.2

To re-elect Dr. Steve Cutler

71,566,816

70,903,974

632,917

29,925

1.3

To re-elect Mr. Rónán Murphy

71,566,816

69,894,181

1,641,749

30,886

1.4

To elect Dr. John Climax

71,566,816

70,821,384

718,792

26,640

1.5

To elect Mr. Eugene McCague

71,566,816

68,831,265

1,329,888

1,405,663

1.6 

To elect Ms. Joan Garahy

71,566,816

70,288,846

1,254,430

23,540

1.7

To elect Ms. Julie O’Neill

71,566,816

69,926,700

1,616,658

23,458

1.8

To elect Dr. Linda Grais

71,566,816

71,142,315

400,259

24,242

2

To receive accounts and reports

71,566,816

71,313,021

37,082

216,713

3

To authorise the fixing of the auditors’ remuneration

71,566,816

65,266,861

6,274,208

25,747

4

To authorise the Company to allot shares

71,566,816

70,341,037

1,193,501

32,278

5**

To disapply pre-emption rights

71,566,816

69,227,283

2,262,331

77,202

6**

To authorise the Company to make market purchases of shares

71,566,816

70,734,103

605,870

226,843

7**

To authorise the price range at which the Company can reissue shares it holds as treasury shares

71,566,816

70,966,963

534,802

65,051

** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.

This press release contains forward-looking statements. These statements are based on management’s current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word “expected” and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC’s website at http://www.sec.gov.

ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,160 employees in 108 locations in 53 countries as at June 30, 2023. For further information about ICON, visit: www.iconplc.com.

Source: ICON plc

ICON/ICLR-F

Contacts

Investor Relations +1888 381 7923 or

Brendan Brennan Chief Financial Officer +353 1 291 2000

Kate Haven Vice President Investor Relations +1888 381 7923

All at ICON.

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.